Evidence map›Paper›PMID 35317515›Full record

ArticleMolecular therapy oncolytics2022

CIP4 targeted to recruit GTP-Cdc42 involving in invadopodia formation via NF-κB signaling pathway promotes invasion and metastasis of CRC.

Zhiyan Hu, Jiaxian Zhu, Yidan Ma, Ting Long, Lingfang Gao, Yan Zhong, Xiaoyan Wang, Zuguo Li

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. ACS omega · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zhiyan HuDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 Guangdong Province, P.R. China.
Jiaxian ZhuDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518101 Guangdong Province, P.R. China.
Yidan MaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 Guangdong Province, P.R. China.
Ting LongDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518101 Guangdong Province, P.R. China.
Lingfang GaoDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515 Guangdong Province, P.R. China.
Yan ZhongDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518101 Guangdong Province, P.R. China.
Xiaoyan WangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 Guangdong Province, P.R. China.
Zuguo LiDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518101 Guangdong Province, P.R. China.
Key Laboratory of Guangdong Province · CNSouthern Medical University Shenzhen Hospital · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cdc42-interacting protein 4 (CIP4), a member of the F-BAR family, which plays an important role in regulating cell membrane and actin, has been reported to interact with Cdc42 and be closely associated with tumor invadopodia formation. In this study, we found that CIP4 expression was significantly higher in human CRC tissues and correlated with the CRC infiltrating depth and metastasis, as well as the lower survival rate in patients. In cultured CRC cells, knockdown of CIP4 inhibited cell migration and invasion ability

Indexed as

Cdc42CIP4colorectal cancerinvadopodiainvasionmetastasisNF-κB

Identifiers

PMID35317515
PMCPMC8924540
OpenAlexW4212967666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.